Telix Pharmaceuticals (TLX) Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Current Assets for 3 consecutive years, with $330.3 million the latest figure, recorded in Q4 2025.

• Quarterly Current Assets fell 49.09% year-over-year to $330.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $330.3 million (down 49.09% YoY) and the FY2025 annual result came in at $330.3 million, down 42.07% from the prior year.
• Current Assets retreated to $330.3 million in Q4 2025 per TLX's latest filing, from $648.7 million in the prior quarter.
• Over the last five years, Current Assets for TLX reached as high as $648.7 million in Q4 2024 and fell as low as $164.2 million in Q4 2023.
• A 3-year average of $381.1 million and a median of $330.3 million in 2025 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets soared 295.07% — and 2025, when it plunged 49.09%.
• Year by year, Current Assets stood at $164.2 million in 2023, then surged by 295.07% to $648.7 million in 2024, then tumbled by 49.09% to $330.3 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $330.3 million, $648.7 million, and $164.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.